Medtech Revenues Hit Record $650bn in 2025, EY Report Finds

By Amara Osei

The global medtech industry posted record revenues of $650bn in 2025, according to EY's latest Pulse of the Medtech Industry report. The figure marks an all-time high for the sector, as reported by Medtech Insight on the survey's release. Artificial intelligence remains the industry's central focus, the report finds.

That combination — a record top line and a sustained AI push — defines the sector's current position. EY's annual pulse survey is one of the most closely watched barometers of medtech performance, and its 2025 reading confirms the industry has moved past the revenue pressure of the post-pandemic reset years into new territory.

What does the $650bn figure tell us?

The headline number is straightforward: $650bn in revenues for 2025, the highest the sector has ever recorded. EY attributes the record in its report, and Medtech Insight relayed the finding without qualification.

For investors and operators, the significance is twofold. First, the sector's revenue base has reached a scale that puts medtech alongside the largest categories in global healthcare. Second, a record year gives companies the balance-sheet flexibility to keep funding the technology bets — above all in AI — that EY identifies as the industry's focus.

The report's framing matters here. EY doesn't present AI as an emerging side project. It presents it as the focus: the technology the industry is organizing its product roadmaps, R&D spending and commercial strategies around.

Why does AI stay at the top of the agenda?

The persistence of AI as the sector's priority is the report's second headline finding, and arguably its more consequential one. Revenue records get broken; strategic direction compounds.

Medtech's AI agenda spans the value chain. Device makers are embedding algorithms into diagnostics, imaging and monitoring hardware. Payers and providers are pressing suppliers for tools that improve clinical outcomes and cut administrative cost. EY's finding that AI "remains" the focus signals continuity: this is the second consecutive cycle in which the technology has topped the industry's priority list, not a fresh inflection.

That continuity has a commercial logic. A sector generating $650bn in annual revenue can afford sustained, multi-year investment in AI without betting the balance sheet on any single application. The risk shifts from affordability to execution — which vendors actually convert algorithmic capability into reimbursed, regulated products.

What should watchers take from the report?

Three readings stand out from EY's 2025 pulse survey:

• Scale. Medtech revenues hit $650bn in 2025 — a record for the industry, per EY.
• Direction. AI remains the sector's focus area, the report states, extending the technology's run as the industry's central investment theme.
• Momentum. A record revenue year combined with an unchanged strategic priority suggests the industry sees its AI buildout as funded by current operations, not by future promises.

The competitive question the report sets up is execution. With the industry's revenue base at an all-time high and its strategic direction settled, differentiation in medtech will come from which companies convert that $650bn engine into AI-driven products fastest — and from how quickly regulators and payers keep pace with what vendors ship.

EY's next pulse reading will show whether the sector holds both the record top line and its AI focus through 2026 — and whether any challenger priority displaces artificial intelligence for the first time in years.